Cargando…
A pharmacoeconomic analysis to determine the relative cost-effectiveness of bimatoprost 0.03% eye drops and brimonidine 0.2% eye drops in patients of primary open-angle glaucoma/ocular hypertension
AIMS: The aim was to compare efficacy and cost-effectiveness of bimatoprost 0.03% and brimonidine 0.2% in primary open-angle glaucoma (POAG)/ocular hypertension (OHT). SETTINGS AND DESIGN: Open, randomized, cross-over, comparative study. MATERIALS AND METHODS: Forty patients of POAG or OHT with intr...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4313493/ https://www.ncbi.nlm.nih.gov/pubmed/25579357 http://dx.doi.org/10.4103/0301-4738.149134 |
_version_ | 1782355228649062400 |
---|---|
author | Natt, Navreet Kaur Gupta, A Singh, G Singh, T |
author_facet | Natt, Navreet Kaur Gupta, A Singh, G Singh, T |
author_sort | Natt, Navreet Kaur |
collection | PubMed |
description | AIMS: The aim was to compare efficacy and cost-effectiveness of bimatoprost 0.03% and brimonidine 0.2% in primary open-angle glaucoma (POAG)/ocular hypertension (OHT). SETTINGS AND DESIGN: Open, randomized, cross-over, comparative study. MATERIALS AND METHODS: Forty patients of POAG or OHT with intraocular pressure (IOP) <30 mm Hg were included in the study after a written informed consent. The patients were divided randomly into two groups of 20 patients each. Patients of group A were administered bimatoprost 0.03% eye drops once daily, and those of group B brimonidine 0.2% eye drops twice daily for a period of 4 weeks. After a washout period of 4 weeks, the patients were crossed over that is, group A was administered brimonidine 0.2% and group B bimatoprost 0.03%. Fall in IOP at 4 weeks was recorded. The daily cost of each drug was calculated by maximum retail price and the average number of drops per bottle. The cost-effectiveness was then calculated as the cost of drug/mm Hg fall in IOP. STATISTICS: Independent samples t-test was used to compare the efficacy of both drugs. RESULTS: IOP lowering with bimatoprost (8.9 ± 1.598 mm Hg) was significantly (P < 0.0001) higher than brimonidine (6.55 ± 1.26 mm Hg). The number of drops/ml were 33.43 ± 0.52 and 25.49 ± 0.26, respectively, for bimatoprost and brimonidine. Treatment with bimatoprost was costlier than brimonidine with daily costs/eye Rs. 4.02 ± 0.06 and 3.14 ± 0.03, yearly costs/eye Rs. 1467.46 ± 20.74 and 1147.75 ± 11.15, respectively. Bimatoprost was more cost-effective than brimonidine with the cost-effectiveness ratio (CER) respectively Rs. 13.10 ± 2.61/mm Hg and Rs. 13.96 ± 2.86/mm Hg. Incremental CER Rs. 10.43/mm Hg implies lower costs/mm Hg extra IOP lowering by bimatoprost than Rs. 13.96 for brimonidine. CONCLUSION: In spite of being costlier, bimatoprost is more efficacious and cost-effective than brimonidine. |
format | Online Article Text |
id | pubmed-4313493 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-43134932015-02-05 A pharmacoeconomic analysis to determine the relative cost-effectiveness of bimatoprost 0.03% eye drops and brimonidine 0.2% eye drops in patients of primary open-angle glaucoma/ocular hypertension Natt, Navreet Kaur Gupta, A Singh, G Singh, T Indian J Ophthalmol Original Article AIMS: The aim was to compare efficacy and cost-effectiveness of bimatoprost 0.03% and brimonidine 0.2% in primary open-angle glaucoma (POAG)/ocular hypertension (OHT). SETTINGS AND DESIGN: Open, randomized, cross-over, comparative study. MATERIALS AND METHODS: Forty patients of POAG or OHT with intraocular pressure (IOP) <30 mm Hg were included in the study after a written informed consent. The patients were divided randomly into two groups of 20 patients each. Patients of group A were administered bimatoprost 0.03% eye drops once daily, and those of group B brimonidine 0.2% eye drops twice daily for a period of 4 weeks. After a washout period of 4 weeks, the patients were crossed over that is, group A was administered brimonidine 0.2% and group B bimatoprost 0.03%. Fall in IOP at 4 weeks was recorded. The daily cost of each drug was calculated by maximum retail price and the average number of drops per bottle. The cost-effectiveness was then calculated as the cost of drug/mm Hg fall in IOP. STATISTICS: Independent samples t-test was used to compare the efficacy of both drugs. RESULTS: IOP lowering with bimatoprost (8.9 ± 1.598 mm Hg) was significantly (P < 0.0001) higher than brimonidine (6.55 ± 1.26 mm Hg). The number of drops/ml were 33.43 ± 0.52 and 25.49 ± 0.26, respectively, for bimatoprost and brimonidine. Treatment with bimatoprost was costlier than brimonidine with daily costs/eye Rs. 4.02 ± 0.06 and 3.14 ± 0.03, yearly costs/eye Rs. 1467.46 ± 20.74 and 1147.75 ± 11.15, respectively. Bimatoprost was more cost-effective than brimonidine with the cost-effectiveness ratio (CER) respectively Rs. 13.10 ± 2.61/mm Hg and Rs. 13.96 ± 2.86/mm Hg. Incremental CER Rs. 10.43/mm Hg implies lower costs/mm Hg extra IOP lowering by bimatoprost than Rs. 13.96 for brimonidine. CONCLUSION: In spite of being costlier, bimatoprost is more efficacious and cost-effective than brimonidine. Medknow Publications & Media Pvt Ltd 2014-12 /pmc/articles/PMC4313493/ /pubmed/25579357 http://dx.doi.org/10.4103/0301-4738.149134 Text en Copyright: © Indian Journal of Ophthalmology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Natt, Navreet Kaur Gupta, A Singh, G Singh, T A pharmacoeconomic analysis to determine the relative cost-effectiveness of bimatoprost 0.03% eye drops and brimonidine 0.2% eye drops in patients of primary open-angle glaucoma/ocular hypertension |
title | A pharmacoeconomic analysis to determine the relative cost-effectiveness of bimatoprost 0.03% eye drops and brimonidine 0.2% eye drops in patients of primary open-angle glaucoma/ocular hypertension |
title_full | A pharmacoeconomic analysis to determine the relative cost-effectiveness of bimatoprost 0.03% eye drops and brimonidine 0.2% eye drops in patients of primary open-angle glaucoma/ocular hypertension |
title_fullStr | A pharmacoeconomic analysis to determine the relative cost-effectiveness of bimatoprost 0.03% eye drops and brimonidine 0.2% eye drops in patients of primary open-angle glaucoma/ocular hypertension |
title_full_unstemmed | A pharmacoeconomic analysis to determine the relative cost-effectiveness of bimatoprost 0.03% eye drops and brimonidine 0.2% eye drops in patients of primary open-angle glaucoma/ocular hypertension |
title_short | A pharmacoeconomic analysis to determine the relative cost-effectiveness of bimatoprost 0.03% eye drops and brimonidine 0.2% eye drops in patients of primary open-angle glaucoma/ocular hypertension |
title_sort | pharmacoeconomic analysis to determine the relative cost-effectiveness of bimatoprost 0.03% eye drops and brimonidine 0.2% eye drops in patients of primary open-angle glaucoma/ocular hypertension |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4313493/ https://www.ncbi.nlm.nih.gov/pubmed/25579357 http://dx.doi.org/10.4103/0301-4738.149134 |
work_keys_str_mv | AT nattnavreetkaur apharmacoeconomicanalysistodeterminetherelativecosteffectivenessofbimatoprost003eyedropsandbrimonidine02eyedropsinpatientsofprimaryopenangleglaucomaocularhypertension AT guptaa apharmacoeconomicanalysistodeterminetherelativecosteffectivenessofbimatoprost003eyedropsandbrimonidine02eyedropsinpatientsofprimaryopenangleglaucomaocularhypertension AT singhg apharmacoeconomicanalysistodeterminetherelativecosteffectivenessofbimatoprost003eyedropsandbrimonidine02eyedropsinpatientsofprimaryopenangleglaucomaocularhypertension AT singht apharmacoeconomicanalysistodeterminetherelativecosteffectivenessofbimatoprost003eyedropsandbrimonidine02eyedropsinpatientsofprimaryopenangleglaucomaocularhypertension AT nattnavreetkaur pharmacoeconomicanalysistodeterminetherelativecosteffectivenessofbimatoprost003eyedropsandbrimonidine02eyedropsinpatientsofprimaryopenangleglaucomaocularhypertension AT guptaa pharmacoeconomicanalysistodeterminetherelativecosteffectivenessofbimatoprost003eyedropsandbrimonidine02eyedropsinpatientsofprimaryopenangleglaucomaocularhypertension AT singhg pharmacoeconomicanalysistodeterminetherelativecosteffectivenessofbimatoprost003eyedropsandbrimonidine02eyedropsinpatientsofprimaryopenangleglaucomaocularhypertension AT singht pharmacoeconomicanalysistodeterminetherelativecosteffectivenessofbimatoprost003eyedropsandbrimonidine02eyedropsinpatientsofprimaryopenangleglaucomaocularhypertension |